Changes in treatment of hyperglycemia in a hypertensive type 2 diabetes population as renal function declines

Autor: Jiankang Liu, Alissa R. Segal, Larry A. Weinrauch, Eric Wisniewski, George Bayliss, John A. D'Elia
Rok vydání: 2017
Předmět:
Zdroj: Clinical Kidney Journal
ISSN: 2048-8513
2048-8505
DOI: 10.1093/ckj/sfx020
Popis: Background Cardiovascular complications associated with expensive noninsulin agents for type 2 diabetes are the focus of concern in light of the risk of kidney dysfunction with aging. Head-to-head comparisons are unavailable to guide the choice of new drugs for hyperglycemia in patients with type 2 diabetes, decreased estimated glomerular filtration rate (eGFR) and increased cardiovascular risk. A first approach would be to document current medication choices. Methods All prescriptions for 10 151 patients (5623 males/4528 females) with both type 2 diabetes and hypertension seen two or more times during a 5-year period (2007–12) at Joslin Diabetes Center were evaluated. {mean age 64 years [interquartile range (IQR) 64–65)], body mass index 31 kg/m2 (IQR 30–32) and mean eGFR 78 mL/min/1.73 m2 (IQR 78, 78)}. Results Insulin was used in >60% of patients, metformin in 50% and sulfonylurea derivatives in 25%. Dipeptidyl peptidase 4 (DPP4) and acarbose class drugs were prescribed in 10% of patients, GLP-1 in 8% and other classes [including thiazolidinediones (TZD)] in
Databáze: OpenAIRE